The effect of orlistat on body weight and coronary heart disease risk profile in obese patients:: The Swedish Multimorbidity Study
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients:: The Swedish Multimorbidity Study
复制标题
DOI：
10.1046/j.1365-2796.2000.00720.x
复制
发表时间：
2000-09-01
影响因子：
11.1
通讯作者：
Lindgärde, F
中科院分区：
文献类型：
--
作者：
Lindgärde, F
客观的。评估奥利司他对冠心病高危肥胖患者体重和心血管风险的影响。设计。筛选后，患者进入为期两周的单盲安慰剂导入期，在此期间遵循轻度低热量饮食，然后随机接受每日 3 次奥利司他 120 mg 或安慰剂的双盲治疗，并结合饮食干预，为期 1 年。该研究在瑞典 33 个初级保健中心进行。总共招募了 382 名患有 2 型糖尿病、高胆固醇血症和/或高血压的肥胖成人（体重指数 28-38 kg m(-2)）。其中 376 人被随机分配至奥利司他 (n = 190) 或安慰剂 (n = 186)。主要结果指标。体重、腰围和臀围、血压、血脂、空腹血糖和 HbA1c 的变化。结果。 1 年后，与安慰剂相比，奥利司他组的平均体重减轻明显更大（5.9% vs. 4.6%：P
Objective. To assess the effect of orlistat on body weight and cardiovascular risk amongst obese patients at high coronary risk.Design. After screening, patients entered a two-week single-blind placebo lead-in period, during which they followed a mildly hypocaloric diet, before being randomized to double-blind treatment with either orlistat 120 mg or placebo three times daily, in conjunction with dietary intervention for 1 years.Setting. The study was conducted at 33 primary care centres in Sweden.Subjects. A total of 382 obese adults (body mass index 28-38 kg m(-2)) with type 2 diabetes, hypercholesterolaemia and/or hypertension were recruited. of whom 376 were randomized to orlistat (n = 190) or placebo (n = 186).Main outcome measures. Change in body weight, waist and hip circumferences, blood pressure, serum lipid profile, fasting glucose and HbA1c.Results. After 1 years, mean weight loss was significantly greater with orlistat compared with placebo (5.9% vs. 4.6%: P